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Intestinal-type adenocarcinoma (ITAC) is one of the most frequent sinonasal tumors, especially in European
countries. The purpose of this article is to review the most recent literature, with special emphasis on
biological and genetic profile and treatment guidelines.
Recent findings
Results on large series support transnasal endoscopic surgery as the technique of choice in the large
majority of patients with ITAC. Adjuvant radiotherapy is recommended in advanced-stage and high-grade
lesions. More robust data are required to confirm that early-stage, low-grade lesions can be treated with
exclusive surgery. The efficacy of new chemotherapy and biotherapy regimens and the added value of
heavy particle radiotherapy are currently under evaluation. With a 5-year overall survival ranging between
53 and 83%, which is mainly impacted by local recurrences, ITAC requires a more detailed understanding
of its biology. Genetic and biological studies have identified alterations in the molecular pathways of
EGFR, MET, and H-RAS which might be considered as potential targets for biotherapy.
Summary
Surgery still plays a key role in the treatment of ITAC, but multidisciplinary management is mandatory.
Although further validation is needed, the role of nonsurgical treatment strategies is rising, in agreement
with the progresses made in the biological profiling of the disease.
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Intestinal-type adenocarcinoma (ITAC) is one of the
most frequent epithelial, nonsquamous cell tumor
of the sinonasal tract. The preferential site of origin
is commonly identified in the nasoethmoidal com-
plex, but according to the observations of Jankowski
et al. [1], the tumor specifically originates from the
olfactory cleft. Another typical feature of ITAC is
the quite constant association with occupational
exposure to wood dust.
In the last decades, a number of refinements in
the treatment of ITAC have emerged, including
transnasal endoscopic surgery (TES), heavy ion radi-
ation therapy, and chemotherapy as a valuable tool
especially in the neoadjuvant setting. Meanwhile,
progresses in biological and genetic profiling of
ITAC are paving the way toward new target thera-
pies, which need further investigations. The present
review is aimed to provide the reader with the main
background information on ITAC, together with
major advances in the last years.rs Kluwer Health, Inc. All rights rese
 Kluwer Health, Inc. UnaEPIDEMIOLOGY
ITAC is a rare tumor with heterogeneous worldwide
incidence and sex distribution. In Europe, the age-
standardized incidence per 100000 person-years
accounts for 0.26 cases in men and 0.04 in women
[2
&
], whereas in the United States, these values are
0.058 in men and 0.034 in women [3]. Accordingly,
ITAC is one of the most frequent sinonasal cancers
in Europe, whereas it is much rarer in the United
States. Similarly, the prevalence in men is remark-
ably variable, with a men-to-women ratio rangingrved. www.co-otolaryngology.com
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KEY POINTS
 Sinonasal ITAC is a rare tumor, associated with
occupational exposure to wood dust.
 Different histologic subtypes show variable biologic
behavior.
 Transnasal endoscopic surgery is the technique of
choice in the large majority of patients with ITAC;
adjuvant radiotherapy is recommended in advanced-
stage and high-grade lesions.
 Neoadjuvant chemotherapy with a platinum-based
regimen can provide a survival benefit in selected
ITACs with functional p53, whereas genetic and
biological studies have identified alterations in the
molecular pathways of EGFR, MET, and H-RAS, which
might be considered as potential targets for biotherapy.
 The efficacy of heavy particle radiotherapy is currently
under evaluation.
Head and neck oncology
Copfrom 1.07 to 1.39 in the United States up to 6.68 in
Italy (Europe) [2
&
,3,4]. Median age at diagnosis is
64–68 years, with a peak of incidence at 60–69 years
in the United States and 75–84 years in Italy
(Europe) [2
&
,3]. Worldwide, the prevalence of ITAC
overtime is stable; however, a rising incidence has
been observed in some countries (e.g., Denmark)
[2
&
,5]. The disease is associated with a moderately
increased risk of occurrence (odds-ratio: 1.47) and
worse prognosis in blacks compared with whites
[3,4].
The large majority of ITAC (88%) can be attrib-
uted to occupational exposure [2
&
]. Themost impor-
tant risk factor is exposure to wood dust [relative risk
(RR): 29.4], followed by products in the textile
industry (RR: 3.5). Cumulative time of exposure
and latency are widely variable, as reported by our
group: 2–66 and 11–72 years, respectively [6].
Conversely, exposure to formaldehyde, nickel/
chromium compounds, or asbestos, which has been
identified as risk factor for sinonasal cancer, was not
confirmed to play a role in the development of
adenocarcinoma [7,8].HISTOPATHOLOGY
Two main pathological classifications of ITAC are
currently used [9]. According to Barnes [10], five
categories can be identified: papillary (18%), colic
(40%), solid (20%), mucinous (14%), and mixed
(8%). Kleinsasser and Schroeder [11] subdivided
ITAC into four variants: papillary-tubular cylinder
cell, which was further graded from I to III, alveolar
goblet, signet-ring cell, and transitional. Histologic2 www.co-otolaryngology.com
yright © 2018 Wolters Kluwer Health, Inc. Unautdiagnosis is relatively simple, and the differential
diagnosis includes a secondary localization of colo-
rectal adenocarcinoma and low-grade nonintestinal
sinonasal adenocarcinoma [12
&&
].
ITAC and adenocarcinomas of the intestines
show a similar immunophenotypical spectrum: at
immunohistochemistry, both stain positive for
CK20, CDX-2, villin, and MUC2 [12
&&
]. However,
chromogranin A and synaptophysin expression,
which can be found in neuroendocrine cells within
the tumor, is typical of primary ITAC [12
&&
,13].
Positive staining for CK7 supports the diagnosis of
sinonasal ITAC over that of intestinal cancer metas-
tasis, although with low sensitivity [14]. Recently,
the intestinal transcription and epigenetic factor
SATB-2 was identified as an additional marker for
ITAC [15]. However, only the integration of patho-
logical and clinical information can differentiate
ITAC from metastatic colorectal adenocarcinoma,
which accounts for 6.1% of secondary sinonasal
tumors [12
&&
,16].
Differential diagnosis of ITAC from sinonasal
nonintestinal adenocarcinomas is guided by immu-
nohistochemistry, as CK20, CDX-2, and villin only
stain positive in ITACs [12
&&
].CARCINOGENESIS AND GENETICS
Although the carcinogenesis of ITAC is still far from
being fully elucidated, some advances have been
made in the last years.
CLU and LGALS4, which are markers of serous
cells of the sinonasal lamina propria glands, are
upregulated in ITAC, especially in well differenti-
ated forms [17]. Foci of intestinal metaplasia have
been described in close vicinity to ITAC (27.5%),
with a high rate of dysplasia (75%) [18]. TP53 over-
expression and mutation are related to wood expo-
sure in both normal mucosa and ITAC [19,20]. This
evidence suggests that carcinogen(s) contained in
wood dust serves as initiation factor(s) for cells of
the sinonasal mucosal glands, with tumorigenesis
occurring in a multistep fashion similar to other
cancer models. Chronic inflammation, which can
also be triggered by wood dust, might act as promot-
ing factor; however, no information about the pat-
tern of cytokines involved is available and further
research is consequently needed [20]. Moreover,
patients affected by ITAC show a higher rate of
the CYP1A1 codon 461 polymorphism and SDTM1
null genotype compared with the general popula-
tion, suggesting that genetic susceptibility is neces-
sary for tumor development, thus explaining why
most woodworkers are not affected by ITAC [21].
In recent years, the mutational landscape of
ITAC has been better characterized. The spectrumVolume 26  Number 00  Month 2018
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Table 1. The mutational landscape of intestinal-type
adenocarcinoma
Genes involved in
ITAC oncogenesis
Genes and genetic
alterations associated
with aggressive
biological behaviora
ANXA1 (frequent)
ANXA2 (rare)
BRAF (rare)
DCC (rare)
EGFR gain of function (frequent)
EGFR mutation (rare)
HRAS (rare)
KRAS (rare)
MET (frequent)
MYC (rare)
PFOU5F1B (rare)
TP53 (frequent)
4q32-ter
APC
BCL2
CCND1
CDH1
ESR1
GPR124
ORAOV1
PTP4A3
PTPN1
STK11/LKB1
TIMP2
TIMP3
TRAIL
Aneuploidy
4q32-ter
ANXA2
DCC
H-RAS
MET
MYC
PFOU5F1B
PTP4A3
PTPN1
TIMP2
TIMP3
TP53
The hallmarks of aggressive biological behavior are summarized in the right
column. ITAC, intestinal-type adenocarcinoma.
aAdvanced stage at diagnosis, high-grade subtypes (solid, mucinous),
intracranial invasion, survival outcomes.
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Cof copy number alterations is variable (gains at 1q,
3q, 5p, 7, 8q, 11q, 12p, 13q, 20q, and 22 and loss at
3p, 4, 5q, 6q, 8p, 9p, 10q, 16q, 17p, 18q, 19p, and 21)
[20], including chromosomal regions usually
involved in most of the epithelial malignancies
(gains at 7p, 8q, and 20q and losses at 8p and
17p) and others that are typical of ITAC (gains at
3q, 5p, 12p, and 18p and losses at 4q, 19p, and 22q)
[22].
EGFR copy number gain is frequent (45%; with
protein overexpression in 13–21% of cases), espe-
cially in the colonic subtype [23], which has been
attributed to two mechanisms: chromosome seven
polysomy and gene amplification [24,25]. Polys-
omy, which results in aneuploidy, is a clue of chro-
mosomal instability and is associated with poor
prognosis [24,26]. EGFR protein overexpression is
more common in woodworkers (42.8%) than in
leatherworkers (9.5%) and patients without profes-
sional exposure (0%) [25]. Mutations in EGFR (0–
5.5%), K-RAS (5.5–12%), and BRAF (0–5.9%) are
rarely found, are mutually exclusive, and are not
associated with EGFR overexpression [24,27,28].
This feature differentiates ITAC from colorectal
and lung adenocarcinomas, which are commonly
associated with EGFR (only lung), K-RAS, and BRAF
mutations [22]. The mutation in codon 12 or 13 of
K-RAS is thought to be specifically related to wood
dust cause [20]. H-RAS is mutated in 16% of cases
and associated with worse prognosis [20,29].
TP53 mutations, promoter methylation, loss of
heterozygosity at 17p13, and p53 protein over-
expression is found in 18–57%of cases and is related
to the subtype of ITAC [20,30]. Nonfunctional p53
protein is frequent and associated with reduced
chemosensitivity and worse prognosis compared
with patients with a functional protein [31,32].
MET is overproduced in 64% of ITACs; the
underlying mechanism of this gain of function is
not associated with gene amplification and remains
to be determined [33].
Furthermore, a number of other genetic and
epigenetic alterations have been described [20,22,
30,34–40]. The genes involved and those which
are hallmarks of aggressive biological behavior are
summarized in Table 1.
Recently, five clusters of gene copy number
alterations of ITAC were identified, with a remark-
able variability in terms of prognosis; no correlation
either with exposure to well known etiological fac-
tors or with histological subtypes of ITAC (papillary,
colonic, solid, and mucinous) has been found [22].
Rather, the transition from the most differentiated
subtype (papillary) to the least differentiated ITAC
(mucinous) seems to be related to the total amount
of mutations [26].1068-9508 Copyright  2018 Wolters Kluwer Health, Inc. All rights rese
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When a malignant lesion of the sinonasal tract is
suspected based on history and endoscopic findings,
diagnostic work-up should include morphological
imaging followed by biopsy. Contrast-enhanced
MRI is the gold standard. It affords precise soft tissue
characterization with high-contrast resolution,
which discriminates neoplastic tissue from nasal
secretions and inflammatory changes, and defines
any possible critical extension (dural/transdural
involvement, perineural spread, intraorbital exten-
sion, etc.). Computed tomography (CT) provides
additional information on tissue density (i.e., calci-
fications or bony structures), but is frequently
unnecessary in the hands of an expert radiologist.
On MRI, the signal intensity of adenocarcino-
mas varies according to their mucin content, cellu-
larity, and presence of hemorrhagic-necrotic areas.
Mucin-producing adenocarcinomas usually show
spontaneous hyperintensity on T2-weighted images
and gradual enhancement on contrast-enhancedrved. www.co-otolaryngology.com 3
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CopT1-weighted sequences, whereas adenocarcinomas
without mucin production show isointensity to
hypointensity on T2-weighted images. However,
the imaging features of adenocarcinomas are often
indistinguishable from those of other sinonasal
cancers [41].
In view of the key role of histology in guiding
treatment, it is important that biopsy is accurately
obtained and histologic slides are analyzed by a
pathologist with specific expertise. In fact, the rarity
of sinonasal tumors and the wide range of histolo-
gies explain the high rate of diagnostic discrepancies
detected after pathologic revision by expert pathol-
ogists [42,43]. Recently, our group reported a 16.9%
rate of discrepancies when comparing pretreatment
biopsy and definitive histologic examination in a
cohort of 77 patients affected by nasoethmoidal
malignancies entirely managed in a tertiary referral
center. Biopsy reliability rate was primarily influ-
enced by histology, with adenocarcinoma being less
frequently associated with diagnostic error com-
pared with other rarer entities. However, the site,
pattern of growth, radiological features of the lesion,
and clinical–anatomical patient-related variables
(comorbidities, pain-threshold) should be consid-
ered when choosing the surgical procedure for
biopsy. In unfavorable conditions, biopsy under
sedation and local anesthesia or diagnostic debulk-
ing under general anesthesia should be preferred
over outpatient sampling of the tumor [44].
Sinonasal ITAC has a low tendency to lymphatic
dissemination: nodal metastases are rare, account-
ing for 2.4–8.0% at presentation and 1.8–2.4% dur-
ing follow-up, being distinctive of an aggressive
behavior of the tumor [6,45,46]. Cervical metastases
mostly occur at level II and must be confirmed with
ultrasound with or without fine-needle aspiration
cytology. Retrolateropharyngeal nodal metastases
are likely underestimated, but can be easily detected
with MRI or CT. Distant metastases are identified in
1.7% of cases at presentation and 12.8% of cases
during follow-up [47]. At PET, ITAC shows a high-
standard uptake value, which is second only to
sinonasal undifferentiated carcinoma [48]. Conse-
quently, primary regional and distant staging as well
as follow-up may benefit from PET, especially in
advanced-stage and high-grade ITACs [6]. Total
body CT associated with bone scintigraphy can be
a reasonable alternative.TREATMENT
Surgery represents the mainstay of treatment for
ITAC, usually followed by adjuvant intensity-mod-
ulated radiotherapy (IMRT). However, in the era of
histology-driven multimodal treatment strategies4 www.co-otolaryngology.com
yright © 2018 Wolters Kluwer Health, Inc. Unautfor sinonasal cancer [49], the role of chemotherapy
and adrotherapy is gaining prominence.Surgery
Surgical planning is guided by both preoperative
imaging and intraoperative findings. Whatever
the approach, the aim is to perform radical resection
using frozen sections to map the surgical margins.
In the last 15 years, TES has emerged as the
surgical approach of choice for most sinonasal
cancer located in the nasoethmoidal complex
[6,50
&
,51]. External or combined approaches
(craniofacial and cranioendoscopic resection,
respectively) still have a role in selected cases
(i.e., massive brain infiltration, supraorbital dural
extension, nasal bones/facial invasion, massive
involvement of the lacrimal system, and/or orbital
content) [49].
Endoscopic resection with transnasal craniec-
tomy is indicated when the tumor is in contact or
crosses the anterior skull base, to provide an ade-
quate margin of resection. After anterior skull base
resection is performed, a watertight reconstruction
of the dura is required to avoid cerebrospinal fluid
leak. Although the use of pedicled flaps has dramat-
ically decreased this occurrence [52], they are rarely
available due to either direct tumor infiltration or
the need to sacrifice the vascular pedicle. On the
other hand, three-layer reconstruction with ilioti-
bial tract grafts has been validated as a reliable and
safe technique for anterior skull base defects [53,54].
Morbidity of endoscopic surgery for sinonasal
malignancies is limited, with excellent outcomes
in terms of quality of life, hospitalization time,
morbidity, and mortality compared with traditional
external approaches [53,55].
The concept of ‘field of cancerization’ as the
result of wood dust (or other factors) inhalation
led to consider bilateral resection of the ethmoidal
box a paradigm in surgery of ITAC, regardless of the
extent of primary tumor [21]. Against this philoso-
phy, some authors reported good oncological out-
comes even with unilateral resection applied to
strictly lateralized lesions [56]. As shown in a recent
report on olfactory neuroblastoma, a unilateral
resection technique can have the advantage of spar-
ing some olfactory function in approximately half of
patients, although undergoing radiotherapy [57].
However, as data in the literature are not robust
enough to draw definitive conclusions, more strin-
gent posttreatment surveillance is mandatory when
a limited resection is performed.
In view of the low rate of cervical lymph node
metastases at presentation and during follow-up,
elective neck treatment is not indicated [47,58].Volume 26  Number 00  Month 2018
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CRadiotherapy
Photon radiation therapy is usually administrated as
adjuvant treatment after surgery in high-grade and/
or advanced-stage tumors [6]. Recent reports seem to
confirm that early-stage (T1–2), low-grade (papil-
lary/colonic) ITACs can be adequately treated with
radical surgery alone [59,60].
Given the proximity to highly radiosensitive
anatomical structures (i.e., orbital content, optic
nerves, brain), the use of IMRT is strongly recom-
mended over conventional radiation techniques,
with the intent to minimize treatment toxicity [61].
Recently, the role of heavy ion therapy, such as
proton beam radiation therapy, is also emerging:
adjuvant proton beam radiation for sinonasal can-
cers was reported to provide a local control superior
to conventional radiotherapy or IMRT [62,63]. This
is likely due to the possibility to better sharp the
dose gradient in view of the physical features of
heavy particles, thus optimizing the balance
between the need for high dose on the tumor bed
and low dose on neighboring noble structures. Like-
wise, carbon-ion radiation therapy is a promising
strategy for sinonasal adenocarcinoma [64]. In case
of nonresectable tumors, radiotherapywith photons
and/or neutrons, possibly associated with chemo-
therapy, provides a valuable 5-year overall survival
(OS); however, specific data on ITAC are lacking
[65].
Finally, perioperative image-adapted brachy-
therapy has also been proposed for sinonasal cancer
(including ITAC), with 3-year OS of 72% [66].Chemotherapy
The only data available on chemotherapy for sino-
nasal ITAC are based on the Italian experience at the
‘Istituto Nazionale dei Tumori’ in Milan [31,32].
Neoadjuvant chemotherapy with cisplatin, 5-fluo-
rouracil, and leucovorin (PFL) resulted in a patho-
logical complete response (CR) in up to 40%of cases.
The probability to obtain a CR to chemotherapy was
significantly higher in ITACs with functional p53
(58% of cases), including both the wild-type and the
mutated protein with function preservation or gain.
Based on these data, neoadjuvant chemotherapy
with PFL scheme is indicated only for ITACs bearing
functional p53 protein [67]. Apart from this isolated
experience, the role of chemotherapy in the neo-
adjuvant or adjuvant setting in the management of
ITAC has not been systematically investigated.
Local application of fluorouracil after debulking
surgery has also been proposed as primary treatment
for ITAC [68], but theDutch experience has not been
reproduced on a large scale.1068-9508 Copyright  2018 Wolters Kluwer Health, Inc. All rights rese
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Although no clinical data are available on biother-
apy for ITAC, the biological profile resulting from
several preclinical studies and the availability of
an immortalized tumor cell line encourages the
employment of target therapies in the management
of this tumor [20,69]. By virtue of a low incidence of
EGFR, K-RAS, and BRAF mutations and high rate of
EGFR copy number gain, the mutational profile of
ITAC seems particularly fitting to anti-EGFR drugs
[27,28]. Likewise, the high rate of MET mutation
(64%) makes MET inhibitors another interesting
option [20,33]. The subgroup of patients with H-
RAS mutation (16%) may benefit from the adminis-
tration of MAPK/ERK pathway inhibitors, alone or
combined with inhibitors of the cyclin-dependent
kinase-4/6 [20,70]. Specific studies are warranted to
explore the real benefit of these drugs in a clinical
setting.PROGNOSTIC FACTORS AND ONCOLOGIC
OUTCOMES
Oncologic outcomes are influenced by several fac-
tors, such as patient characteristics or biological
features of the tumor. Age higher than 75 years,
male sex, and black race have been identified as
adverse prognostic factors [71]. From a histopatho-
logic perspective, mucinous and solid subtypes are
associated with poor prognosis [47,50
&
,71]. At pre-
sentation, locally advanced tumors, nodal or distant
metastases, and sphenoidal, orbital, dural, or brain
invasion were demonstrated as negative prognosti-
cators [6,33,50
&
,60,71–74]. High proliferation index
and several other biological markers (Table 1) are
significantly associated with worse prognosis [75].
Surgery with free margins and overall adequacy
of primary management are of utmost importance,
as positive margins, local failure, and inadequate
previous treatments are independently associated
with poor prognosis [6,33,50
&
,73,76]. Adjuvant radi-
ation therapy has an independent positive effect on
survival [59,71].
In the largest published series, 5-year overall,
disease-specific, and disease-free survivals are 53–83,
82–83, and 62–74%, respectively [6,46,50
&
,77,78].
Open surgery (i.e., craniofacial resection) is associ-
ated with higher morbidity and a nonnegligible
mortality rate [45,51,55]. The recurrence rate after
definitive treatment ranges from 17.6 to 49.6%, with
local, regional, and distant relapse accounting for
16.0–38.2, 1.8–2.4, and 6.5–12.8%, respectively
[6,46,47,50
&
,78]. Accordingly, postoperative surveil-
lance should mainly focus on the primary site,
by including endoscopic examination and MRI (orrved. www.co-otolaryngology.com 5
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Copcontrast-enhanced CT) at 3-month and 6-month
intervals for the first 24months, respectively; beyond
this period, both outpatient and imaging evaluations
can be performed every 6 months until year 5 and
subsequently once a year [79–81], in view of the
possibility for ITAC to develop late local recurrences.
Similarly to primary staging, PET/CT imaging can be
considered for high-grade/high-stage ITACs also dur-
ing follow-up. It is worth mentioning that recurrent
ITAC has a remarkably aggressive behavior, which
is similar to that of high-grade histologies (e.g.,
mucosal melanomas, sinonasal undifferentiated
carcinomas, sinonasal neuroendocrine carcinomas,
sarcomas) [82].CONCLUSION
Sinonasal ITAC is a rare tumor with variable biologic
behavior in relation to the histologic subtype. TES
has emerged as an appropriate primary treatment for
most ITACs. Adjuvant IMRT is recommended in
advanced lesions and high-grade tumors. The pos-
sibility to avoid any adjuvant treatment in early-
stage, radically excised, low-grade lesions should be
further explored. Neoadjuvant chemotherapy with
a platinum-based regimen can provide a survival
benefit in selected ITACs with functional p53.
Although the biology of ITAC is far from being
fully elucidated, recent advances in understanding
the carcinogenetic mechanisms and genetic
alterations involved in the tumor may contribute
to defining a role for biotherapy in the therapeutic
armamentarium.
Acknowledgements
We would like to thank Dr Davide Mattavelli and
Dr Alberto Schreiber for the precious assistance provided
for the preparation of the study.
Financial support and sponsorship
None.
Conflicts of interest
There are no conflicts of interest.REFERENCES AND RECOMMENDED
READING
Papers of particular interest, published within the annual period of review, have
been highlighted as:
& of special interest
&& of outstanding interest1. Jankowski R, Georgel T, Vignaud JM, et al. Endoscopic surgery reveals that
woodworkers’ adenocarcinomas originate in the olfactory cleft. Rhinology
2007; 45:308–314.
2.
&
Binazzi A, Corfiati M, Di Marzio D, et al. Sinonasal cancer in the Italian national
surveillance system: epidemiology, occupation, and public health implica-
tions. Am J Ind Med 2017; doi: 10.1002/ajim.22789. [Epub ahead of print]
The article describes the clinical characteristics and occupational exposures of a
cohort of more than 1500 sinonasal cancer cases.6 www.co-otolaryngology.com
yright © 2018 Wolters Kluwer Health, Inc. Unaut3. Kilic S, Samarrai R, Kilic SS, et al. Incidence and survival of sinonasal
adenocarcinoma by site and histologic subtype. Acta Otolaryngol 2017;
1–7; doi: 10.1080/00016489.2017.1401229. [Epub ahead of print]
4. D’Aguillo CM, Kanumuri VV, Khan MN, et al. Demographics and survival
trends of sinonasal adenocarcinoma from 1973 to 2019. Int Forum Allergy
Rhinol 2014; 4:771–776.
5. Youlden DR, Cramb SM, Peters S, et al. International comparisons of the
incidence and mortality of sinonasal cancer. Cancer Epidemiol 2013;
37:770–779.
6. Nicolai P, Schreiber A, Bolzoni Villaret A, et al. Intestinal type adenocarcinoma
of the ethmoid: outcomes of a treatment regimen based on endoscopic
surgery with or without radiotherapy. Head Neck 2016; 38(Suppl 1):
E996–E1003.
7. Binazzi A, Ferrante P, Marinaccio A. Occupational exposure and sinonasal
cancer: a systematic review and meta-analysis. BMC Cancer 2015;
15:49.
8. Andersson M, Selin F, Jarvholm B. Asbestos exposure and the risk of
sinonasal cancer. Occup Med (Lond) 2016; 66:326–331.
9. Stelow EB, Franchi A, Wenig BM. Intestinal-type adenocarcinoma. In: El-
Naggar AK, Chan JCK, Grandis JR, et al., editors. WHO classification of head
and neck tumours. Lyon: International Agency for Research on Cancer
(IARC); 2017.
10. Barnes L. Intestinal-type adenocarcinoma of the nasal cavity and paranasal
sinuses. Am J Surg Pathol 1986; 10:192–202.
11. Kleinsasser O, Schroeder HG. The pathology and clinical picture of adeno-
carcinoma of the nose after wood dust exposure. Strahlenther Onkol 1989;
165:437–440.
12.
&&
Leivo I. Intestinal-type adenocarcinoma: classification, immunophenotype,
molecular features and differential diagnosis. Head Neck Pathol 2017;
11:295–300.
The article provides an update on current histopathologic classification of intest-
inal-type adenocarcinoma (ITAC), immunophenotypic properties, recent advances
in molecular pathologic features, and differential diagnostic considerations.
13. Projetti F, Serrano E, Vergez S, et al. Is neuroendocrine differentiation
useful to discriminate primary sinonasal intestinal-type adenocarcinomas
from metastatic colorectal adenocarcinomas? J Clin Pathol 2015; 68:
79–82.
14. Franchi A, Massi D, Palomba A, et al. CDX-2, cytokeratin 7 and cytokeratin 20
immunohistochemical expression in the differential diagnosis of primary
adenocarcinomas of the sinonasal tract. Virchows Arch 2004; 445:
63–67.
15. Skalova A, Sar A, Laco J, et al. The role of SATB2 as a diagnostic marker
of sinonasal intestinal-type adenocarcinoma. Appl Immunohistochem Mol
Morphol 2016; doi: 10.1097/PAI.0000000000000388. [Epub ahead of
print]
16. Mills SE, Fechner RE, Cantrell RW. Aggressive sinonasal lesion resembling
normal intestinal mucosa. Am J Surg Pathol 1982; 6:803–809.
17. Tripodi D, Quemener S, Renaudin K, et al. Gene expression profiling in
sinonasal adenocarcinoma. BMC Med Genomics 2009; 2:65.
18. Franchi A, Palomba A, Miligi L, et al. Intestinal metaplasia of the sinonasal
mucosa adjacent to intestinal-type adenocarcinoma. A morphologic, immu-
nohistochemical, and molecular study. Virchows Arch 2015; 466:161–168.
19. Perez-Escuredo J, Martinez JG, Vivanco B, et al. Wood dust-related muta-
tional profile of TP53 in intestinal-type sinonasal adenocarcinoma. Hum Pathol
2012; 43:1894–1901.
20. Hoeben A, van de Winkel L, Hoebers F, et al. Intestinal-type sinonasal
adenocarcinomas: the road to molecular diagnosis and personalized treat-
ment. Head Neck 2016; 38:1564–1570.
21. Cantu G, Solero CL, Mariani L, et al. Intestinal type adenocarcinoma of the
ethmoid sinus in wood and leather workers: a retrospective study of 153
cases. Head Neck 2011; 33:535–542.
22. Lopez-Hernandez A, Perez-Escuredo J, Vivanco B, et al. Genomic profiling of
intestinal-type sinonasal adenocarcinoma reveals subgroups of patients with
distinct clinical outcomes. Head Neck 2017; doi: 10.1002/hed.24941. [Epub
ahead of print]
23. Szablewski V, Solassol J, Poizat F, et al. EGFR expression and KRAS and
BRAF mutational status in intestinal-type sinonasal adenocarcinoma. Int J Mol
Sci 2013; 14:5170–5181.
24. Projetti F, Durand K, Chaunavel A, et al. Epidermal growth factor receptor
expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-
type adenocarcinomas. Hum Pathol 2013; 44:2116–2125.
25. Franchi A, Fondi C, Paglierani M, et al. Epidermal growth factor receptor
expression and gene copy number in sinonasal intestinal type adenocarci-
noma. Oral Oncol 2009; 45:835–838.
26. Hermsen MA, Llorente JL, Perez-Escuredo J, et al. Genome-wide analysis of
genetic changes in intestinal-type sinonasal adenocarcinoma. Head Neck
2009; 31:290–297.
27. Garcia-Inclan C, Lopez F, Perez-Escuredo J, et al. EGFR status and KRAS/
BRAF mutations in intestinal-type sinonasal adenocarcinomas. Cell Oncol
2012; 35:443–450.
28. Franchi A, Innocenti DR, Palomba A, et al. Low prevalence of K-RAS, EGF-R
and BRAF mutations in sinonasal adenocarcinomas. Implications for anti-
EGFR treatments. Pathol Oncol Res 2014; 20:571–579.Volume 26  Number 00  Month 2018
horized reproduction of this article is prohibited.
CE: Swati; MOO/260214; Total nos of Pages: 7;
MOO 260214
Intestinal-type adenocarcinoma of the sinonasal tract Rampinelli et al.
C29. Perez P, Dominguez O, Gonzalez S, et al. ras Gene mutations in ethmoid sinus
adenocarcinoma: prognostic implications. Cancer 1999; 86:255–264.
30. Re M, Magliulo G, Tarchini P, et al. p53 and BCL-2 over-expression inversely
correlates with histological differentiation in occupational ethmoidal intestinal-
type sinonasal adenocarcinoma. Int J Immunopathol Pharmacol 2011;
24:603–609.
31. Licitra L, Suardi S, Bossi P, et al. Prediction of TP53 status for primary
cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intest-
inal-type adenocarcinoma. J Clin Oncol 2004; 22:4901–4906.
32. Bossi P, Perrone F, Miceli R, et al. Tp53 status as guide for the management of
ethmoid sinus intestinal-type adenocarcinoma. Oral Oncol 2013; 49:
413–419.
33. Projetti F, Mesturoux L, Coulibaly B, et al. Study of MET protein levels and MET
gene copy number in 72 sinonasal intestinal-type adenocarcinomas. Head
Neck 2015; 37:1563–1568.
34. Franchi A, Palomba A, Fondi C, et al. Immunohistochemical investigation of
tumorigenic pathways in sinonasal intestinal-type adenocarcinoma. A tissue
microarray analysis of 62 cases. Histopathology 2011; 59:98–105.
35. Perez-Escuredo J, Lopez-Hernandez A, Costales M, et al. Recurrent DNA
copy number alterations in intestinal-type sinonasal adenocarcinoma. Rhinol-
ogy 2016; 54:278–286.
36. Chiang JM, Chen TC. A Peutz-Jeghers syndrome family associated with
sinonasal adenocarcinoma: 28 years follow up report. Fam Cancer 2017;
16:555–560.
37. Costales M, Lopez-Hernandez A, Garcia-Inclan C, et al. Gene methylation
profiling in sinonasal adenocarcinoma and squamous cell carcinoma. Otolar-
yngol Head Neck Surg 2016; 155:808–815.
38. Diaz-Molina JP, Llorente JL, Vivanco B, et al. Wnt-pathway activation in
intestinal-type sinonasal adenocarcinoma. Rhinology 2011; 49:593–599.
39. Re M, Santarelli A, Mascitti M, et al. Trail overexpression inversely correlates
with histological differentiation in intestinal-type sinonasal adenocarcinoma.
Int J Surg Oncol 2013; 2013:203873.
40. Rodrigo JP, Garcia-Pedrero JM, Llorente JL, et al. Down-regulation of annexin
A1 and A2 protein expression in intestinal-type sinonasal adenocarcinomas.
Hum Pathol 2011; 42:88–94.
41. Kawaguchi M, Kato H, Tomita H, et al. Imaging characteristics of malignant
sinonasal tumors. J Clin Med 2017; 6:116.
42. Kronz JD, Westra WH. The role of second opinion pathology in the manage-
ment of lesions of the head and neck. Curr Opin Otolaryngol Head Neck Surg
2005; 13:81–84.
43. Mehrad M, Chernock RD, El-Mofty SK, Lewis JS Jr. Diagnostic discrepancies in
mandatory slide review of extradepartmental head and neck cases: experience
at a large academic center. Arch Pathol Lab Med 2015; 139:1539–1545.
44. Schreiber A, Rampinelli V, Ferrari M, et al. Diagnostic reliability of pretreatment
biopsy in malignant naso-ethmoidal tumors: a retrospective study on 78
cases. Laryngoscope 2018; doi: 10.1002/lary.27077. [Epub ahead of print]
45. Mortuaire G, Leroy X, Vandenhende-Szymanski C, et al. Comparison of
endoscopic and external resections for sinonasal instestinal-type adenocar-
cinoma. Eur Arch Otorhinolaryngol 2016; 273:4343–4350.
46. Vergez S, du Mayne MD, Coste A, et al. Multicenter study to assess
endoscopic resection of 159 sinonasal adenocarcinomas. Ann Surg Oncol
2014; 21:1384–1390.
47. Donhuijsen K, Kollecker I, Petersen P, et al. Metastatic behaviour of sinonasal
adenocarcinomas of the intestinal type (ITAC). Eur Arch Otorhinolaryngol
2016; 273:649–654.
48. Felix-Ravelo M, Bey A, Arous F, et al. Relationship between (18)FDG-PET and
different types of sinonasal malignancies. Acta Otolaryngol 2017; 137:191–195.
49. Castelnuovo P, Turri-Zanoni M, Battaglia P, et al. Sinonasal malignancies of
anterior skull base: histology-driven treatment strategies. Otolaryngol Clin
North Am 2016; 49:183–200.
50.
&
Camp S, Van Gerven L, Poorten VV, et al. Long-term follow-up of 123 patients
with adenocarcinoma of the sinonasal tract treated with endoscopic resection
and postoperative radiation therapy. Head Neck 2016; 38:294–300.
This is a large and homogeneous series of patients affected by ITAC of the
sinonasal tract, showing that in well selected patients and with appropriate use of
adjuvant therapy, endoscopic resection of sinonasal adenocarcinoma results in
good oncologic outcomes.
51. Meccariello G, Deganello A, Choussy O, et al. Endoscopic nasal versus open
approach for the management of sinonasal adenocarcinoma: a pooled-ana-
lysis of 1826 patients. Head Neck 2016; 38(Suppl 1):E2267–E2274.
52. Klatt-Cromwell CN, Thorp BD, Del Signore AG, et al. Reconstruction of skull
base defects. Otolaryngol Clin North Am 2016; 49:107–117.
53. Mattavelli D, Schreiber A, Villaret AB, et al. Complications and donor site
morbidity of 3-layer reconstruction with iliotibial tract of the anterior skull base:
retrospective analysis of 186 patients. Head Neck 2018; 40:63–69.
54. Mattavelli D, Schreiber A, Ferrari M, et al. Three-layer reconstruction with
iliotibial tract after endoscopic resection of sinonasal tumors. World Neuro-
surg 2017; 101:486–492.
55. Castelnuovo P, Lepera D, Turri-Zanoni M, et al. Quality of life following
endoscopic endonasal resection of anterior skull base cancers. J Neurosurg
2013; 119:1401–1409.1068-9508 Copyright  2018 Wolters Kluwer Health, Inc. All rights rese
opyright © 2018 Wolters Kluwer Health, Inc. Una56. Van Gerven L, Jorissen M, Nuyts S, et al. Long-term follow-up of 44 patients
with adenocarcinoma of the nasal cavity and sinuses primarily treated with
endoscopic resection followed by radiotherapy. Head Neck 2011; 33:
898–904.
57. Tajudeen BA, Adappa ND, Kuan EC, et al. Smell preservation following
endoscopic unilateral resection of esthesioneuroblastoma: a multiinstitutional
experience. Int Forum Allergy Rhinol 2016; 6:1047–1050.
58. Mirghani H, Hartl D, Mortuaire G, et al. Nodal recurrence of sinonasal cancer:
does the risk of cervical relapse justify a prophylactic neck treatment? Oral
Oncol 2013; 49:374–380.
59. Turri-Zanoni M, Battaglia P, Lambertoni A, et al. Treatment strategies for
primary early-stage sinonasal adenocarcinoma: a retrospective bi-institutional
case–control study. J Surg Oncol 2015; 112:561–567.
60. Choussy O, Ferron C, Vedrine PO, et al. Role of radiotherapy in the treatment
of nasoethmoidal adenocarcinoma. Arch Otolaryngol Head Neck Surg 2010;
136:143–146.
61. Askoxylakis V, Hegenbarth P, Timke C, et al. Intensity modulated radiation
therapy (IMRT) for sinonasal tumors: a single center long-term clinical
analysis. Radiat Oncol 2016; 11:17.
62. Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon
therapy for paranasal sinus and nasal cavity malignant diseases: a systematic
review and meta-analysis. Lancet Oncol 2014; 15:1027–1038.
63. Dagan R, Bryant C, Li Z, et al. Outcomes of sinonasal cancer treated with
proton therapy. Int J Radiat Oncol Biol Phys 2016; 95:377–385.
64. Koto M, Hasegawa A, Takagi R, et al. Feasibility of carbon ion radiotherapy for
locally advanced sinonasal adenocarcinoma. Radiother Oncol 2014;
113:60–65.
65. Chopra S, Kamdar DP, Cohen DS, et al. Outcomes of nonsurgical manage-
ment of locally advanced carcinomas of the sinonasal cavity. Laryngoscope
2017; 127:855–861.
66. Teudt IU, Meyer JE, Ritter M, et al. Perioperative image-adapted brachytherapy
for the treatment of paranasal sinus and nasal cavity malignancies. Bra-
chytherapy 2014; 13:178–186.
67. Bossi P, Saba NF, Vermorken JB, et al. The role of systemic therapy in the
management of sinonasal cancer: a critical review. Cancer Treat Rev 2015;
41:836–843.
68. Knegt PP, Ah-See KW, vd Velden LA, Kerrebijn J. Adenocarcinoma of the
ethmoidal sinus complex: surgical debulking and topical fluorouracil may be
the optimal treatment. Arch Otolaryngol Head Neck Surg 2001; 127:
141–146.
69. Perez-Escuredo J, Garcia Martinez J, Garcia-Inclan C, et al. Establishment and
genetic characterization of an immortal tumor cell line derived from intestinal-
type sinonasal adenocarcinoma. Cell Oncol 2011; 34:23–31.
70. Yadav V, Burke TF, Huber L, et al. The CDK4/6 inhibitor LY2835219 over-
comes vemurafenib resistance resulting from MAPK reactivation and cyclin
D1 upregulation. Mol Cancer Ther 2014; 13:2253–2263.
71. Chen MM, Roman SA, Sosa JA, Judson BL. Predictors of survival in sinonasal
adenocarcinoma. J Neurol Surg B Skull Base 2015; 76:208–213.
72. Howard DJ, Lund VJ, Wei WI. Craniofacial resection for tumors of the nasal
cavity and paranasal sinuses: a 25-year experience. Head Neck 2006;
28:867–873.
73. Suarez C, Llorente JL, Fernandez De Leon R, et al. Prognostic factors in
sinonasal tumors involving the anterior skull base. Head Neck 2004;
26:136–144.
74. Fiaux-Camous D, Chevret S, Oker N, et al. Prognostic value of the seventh
AJCC/UICC TNM classification of intestinal-type ethmoid adenocarcinoma:
systematic review and risk prediction model. Head Neck 2017; 39:668–678.
75. Antognoni P, Turri-Zanoni M, Gottardo S, et al. Endoscopic resection followed
by adjuvant radiotherapy for sinonasal intestinal-type adenocarcinoma:
retrospective analysis of 30 consecutive patients. Head Neck 2015;
37:677–684.
76. Hanna E, DeMonte F, Ibrahim S, et al. Endoscopic resection of sinonasal
cancers with and without craniotomy: oncologic results. Arch Otolaryngol
Head Neck Surg 2009; 135:1219–1224.
77. Lund V, Howard DJ, Wei WI. Endoscopic resection of malignant tumors of the
nose and sinuses. Am J Rhinol 2007; 21:89–94.
78. Bogaerts S, Vander Poorten V, Nuyts S, et al. Results of endoscopic resection
followed by radiotherapy for primarily diagnosed adenocarcinomas of the
paranasal sinuses. Head Neck 2008; 30:728–736.
79. Parasher AK, Kuan EC, John MAS, et al. What is the appropriate timing for
endoscopic and radiographic surveillance following treatment for sinonasal
malignancies? Laryngoscope 2017; doi: 10.1002/lary.27013. [Epub ahead
of print]
80. Workman AD, Palmer JN, Adappa ND. Posttreatment surveillance for sino-
nasal malignancy. Curr Opin Otolaryngol Head Neck Surg 2017; 25:86–92.
81. Maroldi R, Ravanelli M, Farina D, et al. Posttreatment evaluation of paranasal
sinuses after treatment of sinonasal neoplasms. Neuroimaging Clin N Am
2015; 25:667–685.
82. Kaplan DJ, Kim JH, Wang E, Snyderman C. Prognostic indicators for salvage
surgery of recurrent sinonasal malignancy. Otolaryngol Head Neck Surg
2016; 154:104–112.rved. www.co-otolaryngology.com 7
uthorized reproduction of this article is prohibited.
